ArticleCytotechnology2025
miR-675-5p regulation of autophagy by TSC2 promotes cisplatin resistance in ovarian cancer.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autophagy modulation in gynaecologic oncology: insights into immune regulation and therapeutic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is a type of gynecological cancer, characterized by a high mortality rate. MicroRNAs (miRNAs) and cell autophagy are associated with the chemoresistance of tumors. The purpose of this study was to investigate the role of miR-675-5p in cisplatin (DDP) resistance in OC cells and its related mechanism. We collected OC tissues and paracancerous tissues. The OC cell line A2780 and the DDP-resistant cell line A2780/DDP were used for the study. RT-qPCR, Western blot and immunofluorescence were used to detect the expression of related genes and proteins. Cell proliferation and apoptosis were evaluated by CCK-8 assay and flow cytometry. Furthermore, the effect of miR-675-5p on the progression of OC was investigated in a xenograft model of nude mice. In this research, miR-675-5p expression was significantly increased in OC tissues and A2780/DDP cells. The suppression of miR-675-5p in A2780/DDP cells resulted in a significant reduction in DDP resistance. Further study revealed that miR-675-5p inhibited TSC2 expression in OC cells by binding to the TSC2 3'UTR, thereby activating the mTOR signaling pathway and promoting autophagy in A2780/DDP cells. Knocking down miR-675-5p suppressed DDP resistance in A2780/DDP cells through TSC2/mTOR axis, while overexpressing miR-675-5p suppressed DDP sensitivity in A2780 cells through TSC2. The tumor volume was decreased after injection of miR-675-5p-knockdown A2780/DDP cells in vivo. Knocking down miR-675-5p can inhibit the mTOR signaling pathway and autophagy through TSC2, thereby reducing the DDP resistance of OC cells. This may provide a potential therapeutic target for OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.